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 9 
Vibrational spectroscopy can provide rapid, label-free, and objective analysis for the clinical domain. 10 
Spectroscopic analysis of biofluids such as blood components (e.g. serum, plasma) and others in the 11 
proximity of the diseased tissue or cell (e.g. bile, urine, sputum), offer non-invasive 12 
diagnostic/monitoring possibilities for future healthcare that is capable of rapid diagnosis of diseases via 13 
specific spectral markers or signatures. Biofluids offer an ideal diagnostic medium due to their ease and 14 
low cost of collection and daily use in clinical biology. Due to the low risk and invasiveness of their 15 
collection they are widely welcomed by patients as a diagnostic medium. This review underscores recent 16 
research within the field of biofluid spectroscopy and its use in myriad pathologies such as cancer and 17 
infectious diseases. It highlights current progresses, advents, and pitfalls within the field and discusses 18 
future spectroscopic clinical potentials for diagnostics. The requirements and issues surrounding clinical 19 
translation are also considered. 20 
 21 
Keywords: Biospectroscopy, Biofluids, Infrared Spectroscopy, Raman Spectroscopy, Biomarkers, Cancer, Infectious Diseases, 22 
Clinical Implementation, Multivariate Analysis 23 
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Introduction 24 
Biophotonic techniques are widely used in research for developing new modalities 25 
with the aim to improve patient healthcare via better diagnosis, prognosis, and 26 
surveillance. Vibrational spectroscopy holds such promises because the “molecular 27 
fingerprint” that it provides represents a snapshot of the sample biomolecular 28 
composition and variations therein can be exploited to identify different pathologies 29 
1, 2
. Its sensitivity to such variations makes it possible to probe pathophysiological 30 
processes in cells and tissues as demonstrated by many reports for more than a 31 
decade 
3
, leading to the concepts of “spectral cytopathology” and “spectral 32 
histopathology” 
4-6
. With the advances in spectroscopic/imaging technologies and 33 
data processing techniques, cells and tissues can be analysed rapidly and non-34 
invasively to identify disease-related abnormalities. Indeed, some promising studies 35 
have reported the added value of vibrational spectroscopy to deliver an objective 36 
diagnosis but they were performed on a limited number of patients 
7
. In spite of these 37 
advances in cell and tissue spectroscopy, the technique has not yet been able to 38 
overcome the experimental research phase in order to be transferable from bench to 39 
bedside. This is mainly due to the lack of standardisation and validation in large 40 
clinical trials and multicentre actions. Access to large sample sets with ethical 41 
approval is also a limitation. We believe that spectroscopic diagnosis/prognosis via 42 
biofluids represents an interesting alternative to cells and tissues. Presently, there is 43 
limited research representing high-powered clinical studies for biofluid spectroscopy, 44 
yet through the use of animal systems several studies from Naumann’s group have 45 
set the precedent for studies involving large sample numbers; instilling confidence in 46 
the high sensitivity and specificity model outcomes by using several hundred animals 47 
per study 
8-10
. 48 
The quest for disease markers through “liquid biopsies” is a fast emerging field and 49 
has only been recently explored by spectroscopic approaches. Blood components like 50 
serum and plasma are routinely used for blood testing as they contain biomarkers 51 
that are useful for disease diagnostics. For example, in diseases like cancer, they are 52 
known to be a rich source of information and represent readouts of the ongoing 53 
cellular and extracellular events 
11
. Further, they are easily accessible and minimally 54 
invasive for patients making large studies feasible. Other organ-specific biofluids in 55 
the proximity of the diseased cells or tissues like bile, urine, sputum, and 56 
cerebrospinal fluid are also of interest for diagnostic purposes. Recent trends tend to 57 
indicate that the use of single or few biomarkers has fallen out in favour of multiple 58 
biomarkers 
12
 and in this context the role of vibrational spectroscopic methods can be 59 
determinant as the information provided contains information on global sample 60 
biomolecular composition providing a chemical ‘fingerprint’ or ‘signature’ of the 61 
sample. We will focus on the ability of vibrational spectroscopic analysis to illuminate 62 
these disease signatures (disease pattern recognition) for diagnostic purposes as 63 
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opposed to the quantitative determination of specific macromolecules within the 64 
biofluid 
13-15
. 65 
This critical review, from both the spectroscopic and clinical points of view, considers 66 
the issues encountered during translational research aimed at assessing the 67 
potentials of infrared and Raman approaches as rapid and label-free diagnostic 68 
methods for biological fluids. In addition, the techniques can be adapted to a variety 69 
of diseases and therefore represent a cost-effective investment for healthcare 70 
systems. This approach could provide a dynamic diagnostic environment that will 71 
enable rapid diagnostics leading to earlier treatment. In addition, the ability to 72 
accurately and rapidly monitor disease will allow for closer patient follow-up and 73 
earlier change in treatment if needed. This would enable patients to access treatment 74 
earlier with reductions in mortality and morbidity. 75 
 76 
Vibrational Spectroscopy  77 
Vibrational spectroscopy relates to the specific optical techniques of Infrared (IR) and 78 
Raman spectroscopy. These techniques probe intramolecular vibrations and rotations 79 
of the sample when irradiated with light 
16
. The light-matter relationship is 80 
underpinned by the electromagnetic theory postulated by Maxwell 
17
. Vibrational 81 
spectroscopy has been used for analysing a myriad of samples in chemical, physical 82 
and biological applications.  83 
The Raman effect constitutes the spontaneous inelastic light scattering process of 84 
photons following the interaction of a monochromatic radiation (e.g., laser source) 85 
with the sample. During this interaction both elastic and inelastic scattering processes 86 
take place. A high proportion of the photons are elastically scattered with no change 87 
in energy (so no molecular information), known as Rayleigh scattering 
17
. When 88 
photons transfer energy to the molecules as vibrational energy, the energy loss of the 89 
scattered photons corresponds to the vibrational energy levels of the molecules. This 90 
is known as the Raman-Stokes scattering. The incident photons can in turn receive 91 
energy from vibrating molecules, and therefore their frequencies increase, described 92 
as the Raman anti-Stokes scattering. Figure 1 shows the transitions involved during 93 
these three processes. In spontaneous Raman, the Stokes scattering is generally used 94 
due to its higher sensitivity. 95 
 96 
Infrared spectroscopy (IR) is broadly defined as the study of absorption characteristics 97 
arising from the molecular motion of materials due to atomic displacement 
4 
upon 98 
intimate interaction with an infrared source 
18
. Depending on the modality of choice, 99 
the radiation can be either transmitted, internally reflected, reflected, or transflected 100 
(a combination of transmission and reflectance). During the light - matter interaction, 101 
infrared light causes a molecule to enter in a higher vibrational state due to the 102 
transfer of ‘quanta’ or ‘packets’ of energy at certain wavelengths dependent upon the 103 
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composition of the matter under analysis. Figure 1 illustrates the energy level 104 
transition involved in the IR absorption process compared to Raman scattering 105 
showing that vibrational energy levels can be probed with both techniques using 106 
different physical processes. These transitions result in a spectrum constituted of 107 
peaks/bands that can be interpreted qualitatively (peak position) and quantitatively 108 
(peak intensity/area, relative intensity). For IR spectroscopy the bands arise from a 109 
change in the electric dipole moment of the molecules, whereas Raman is associated 110 
with a change in the molecular polarisability. 111 
Constituent chemical molecular bonds present many forms of vibrations which occur 112 
at different energies corresponding to different allowed transitions. IR and Raman 113 
spectroscopies are complementary and provide a “fingerprint” or “signature” of the 114 
molecules contained within the sample depending on whether their bonds exhibit 115 
Raman or IR activities. Certain vibrations that are allowed in Raman may be forbidden 116 
in IR and vice versa. For a full treatise of fundamental spectroscopy works, the 117 
authors direct the reader to two reviews by Barth and Haris on IR spectroscopy 
19
 and 118 
Long on Raman spectroscopy 
20
. 119 
 120 
Biological and Biomedical Vibrational Spectroscopy 121 
There is a continuing effort devoted to the exploration of new technologies that can 122 
detect early signs of diseases and therefore significantly reduce mortality and 123 
morbidity. This depends on the ability to detect biochemical/morphological changes 124 
at an early stage of the disease or before the disease becomes symptomatic. 125 
Detection of biomarkers plays an important role in this exploration, and in the case of 126 
cancer for example, they cover a broad range of biochemical entities, such as nucleic 127 
acids, proteins, carbohydrates, lipids, small metabolites, and cytogenetic and 128 
cytokinetic parameters, as well as entire circulating tumour cells found in body fluids. 129 
They can be used for risk assessment, diagnosis, prognosis, and for the prediction of 130 
treatment efficacy and toxicity and disease recurrence. 131 
 132 
Over the last 20 years, there has been an exponential increase in the number of 133 
studies dedicated to identification of new cancer (Fig. 2a) and infectious disease (Fig. 134 
2b) biomarkers, mainly because of the tremendous development of high throughput 135 
molecular technologies and associated bioinformatics. However, among the huge 136 
amount of candidate biomarkers, only a limited number have been validated for use 137 
in medical practice. A recent paper states that in DNA and proteomic research, out of 138 
1000 biomarkers discovered less than 100 have been validated for routine clinical 139 
practice 
21
. 140 
 141 
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Vibrational spectroscopy can contribute in bringing a new way for searching 142 
biomarkers, namely “spectral signatures” or “spectral biomarkers”, which reflect the 143 
total biochemical composition of the studied sample as it has been employed for cell 144 
and tissue analysis since the pioneering work by Mantsch, Naumann and Diem, to list 145 
just a few. 146 
Biological samples are frequently analysed via the transmission mode in the mid-IR 147 
region, where most molecules absorb and the molecular absorbance is proportional 148 
to concentration, obeying Beer-Lambert’s law for non-scattering samples. Mid-IR 149 
absorption features between approximately 4000 and 400 cm
-1
 (2.5 to 25 μm). 
 
Figure 150 
3 illustrates an example of an FTIR spectrum of a breast tissue with the assignment of 151 
some important biomolecules. The spectrum can be divided into four regions where 152 
the main macromolecules absorb: -CH2 and -CH3 groups of fatty acids and proteins 153 
(3050–2800 cm
-1
); C=O stretching vibrations mainly from lipid esters (1800–1700 cm
-
154 
1
); C=O, N-H, C-N modes from Amide I and II protein bands (1700–1500 cm
-1
); 155 
phosphate vibrations from nucleic acids (1225 and 1080 cm
-1
); and carbohydrate 156 
absorptions (1200-900 cm
-1
). Libraries housing spectra from biological and 157 
biochemical samples have been collected over the years. 158 
 159 
Over the years, variants of IR spectroscopic technologies have been tested. A recent 160 
review highlights the use of IR techniques to probe the functionality of biological and 161 
biomimetic systems 
22
. Their applications to study biological and biomedical 162 
specimens have continuously increased 
23, 24
. When used to analyse biofluids, the 163 
mid-IR or near-IR spectroscopies would be performed on drying samples to negate 164 
the overwhelming water band from obscuring spectra and to increase automation 
25
. 165 
 166 
Another method of obtaining an IR spectrum is when the sample is placed on a highly 167 
reflecting surface, typically aluminium/teflon coated substrates or a glass slide with tin 168 
oxide-based silver reflective coating called low e-slides (e.g., MirrIR). In this case the process 169 
is termed transflection because the IR beam passes through the sample, is reflected off the 170 
slide and passes again through the sample before detection. These substrates have very low 171 
cost but recently they have been shown to cause significant spectral intensity variations, due 172 
to an electric free standing wave artefact (EFSW) 
26, 27
 which could be misinterpreted as 173 
composition variations while it is the sample thickness variation that is questionable. The 174 
fundamental question when using low e-slides is whether the spectral variations observed 175 
due to the EFSW impact on the discriminant spectral differences. In case of thin samples 176 
such as air-dried cellular monolayers, recent research by Cao et al. has shown that the same 177 
classification was obtained when performing transmission and transflection measurements 178 
28
. 179 
Attenuated total reflectance (ATR) FTIR spectroscopy is a promising modality for 180 
biological sample analysis. The guided IR beam propagates through a high refractive 181 
index crystal surface producing an evanescent standing wave that penetrates the 182 
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sample by a few microns. However for proper use, several issues need to be 183 
considered, such as contact between the ATR crystal and the sample, the beam 184 
penetration depth and image distortion due to high refractive indices 
25, 29
. 185 
 186 
Despite its molecular specificity, FTIR spectroscopy suffers from some shortcomings 187 
which limit its application to the measurement of biological samples and their 188 
dynamic behaviour. An important one is sensitivity, in particular in thin samples as a 189 
result of the Beer-Lambert’s law. Signal amplification can be achieved by the 190 
plasmonic resonances of nano-scale metallic particles 
30
, resulting in the phenomena 191 
of surface-enhanced infrared absorption (SEIRA) 
31
, in analogy with surface-enhanced 192 
Raman scattering (SERS) 
32
. Early SEIRA studies utilised metal island films 
22, 31
 and 193 
dried samples, but today plasmonic chip-based technology enables the in situ 194 
monitoring of protein and nanoparticle interactions in aqueous media, at high 195 
sensitivity in real time 
33
. 196 
One method of choice for cell and tissue analysis has been IR microspectroscopy. The 197 
coupling of an FTIR spectrometer with a microscope has helped to perform 198 
microanalysis and gain in spatial resolution ~ 15-20 µm with a thermal source and ~ 5-199 
10 µm with a synchrotron source using single element detectors. These systems are 200 
limited by low sensitivities and time-consuming experiments (several hours) as they 201 
remain a point by point acquisition. In the 1990’s, the advent of imaging devices with 202 
multi-element detectors combined with aperture less microscopes, high-tech 203 
automation and faster computers, have drastically reduced the data acquisition times 204 
(few hours) with resolution going down to ~2µm/pixel with liquid nitrogen cooled 205 
focal plane array detectors. Many research groups have demonstrated the efficacy of 206 
employing this to a clinical setting on biopsy samples; minimising subjectivity and 207 
increasing diagnostic accuracy 
4
. In spite of these progresses, such instruments remain 208 
research machines and are not adapted to be used as benchtop techniques for 209 
routine analysis in a clinical setting.  210 
The launching of new IR imaging devices incorporating high-intensity tunable 211 
quantum cascade lasers (QCL) could revolutionise the way clinical IR images are 212 
acquired 
34
. High-throughput IR chemical imaging is now in its early days, and needs 213 
to be tested and validated. However, a gain of three orders of magnitude in 214 
acquisition time has recently been reported for large samples by Bhargava’s group 
35
. 215 
Combining signal enhancement from SEIRA and fast imaging using a QCL source with 216 
small bandwidths, a recent study claimed a ~ 200 fold gain in imaging time 
36
. 217 
The Raman shift covers the range between 0 and 4000 cm
-1
. Raman spectroscopy can be 218 
used in the confocal mode and with the resonance and surface-enhanced modalities. 219 
Applications of Raman microspectroscopy for probing biological systems have been 220 
continuously expanding over the years along with IR spectroscopy 
37
. Its high spatial 221 
resolution (~0.5 μm with green lasers), compatibility with aqueous environment 
38, 39
, and in 222 
vivo amenability 
40-43
 makes it a good candidate for biological and biomedical research. Akin 223 
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to FTIR, it also provides high content biomolecular information. Microspectroscopy with 224 
immersion measurements can be used to enhance signal to background ratio enabling 225 
higher quality data acquisition as demonstrated by Bonnier et al. 
44
. 226 
Due to its advantages, label-free, high spectral specificity, limited water signal, and the fact 227 
that most biological molecules are Raman active, Raman has been deployed to in vitro cell 228 
and tissue studies, but now significant developments of in vivo work due to the compatibility 229 
with fibres, has enabled Raman endoscopy in a label-free manner and in vivo Raman 230 
probes/endoscopes have made direct tissue analysis possible 
45
.  231 
New fields of measurement and implementation possibilities have multiplied due to recent 232 
hardware developments, improved sampling methods, and advances in the design of Raman 233 
technology alongside developments and advances in multivariate data analysis. It has been 234 
possible to uncover subtle disease-related spectral changes and exploit them in classification 235 
models. However, an important drawback of Raman spectroscopy is that the effect is 236 
inherently weak as a very small proportion of incident photons are scattered (~1 in 10
8
) with 237 
a corresponding change in frequency 
17
. This together with the fact that to date most of the 238 
commercial systems use dispersive configurations adds another limitation compared to fast 239 
IR imaging systems, and makes Raman imaging of biological specimens a slower process. 240 
These limitations can be partly circumvented with other Raman modalities based on 241 
Resonant Raman Scattering (RRS) and Surface-Enhanced Raman Scattering (SERS) to enable 242 
gains in detection sensitivity 
37
. In SERS technology, the use of functionalised metal 243 
nanosurfaces has allowed optimising the enhancement to several orders of magnitude 244 
depending on the metal substrate. Metal nanoparticle arrays and single nanoparticles have 245 
been utilized for high-throughput detection 
46
. SERS has been applied in different areas in 246 
the chemical and biological fields 
47
 and its very high sensitivity has allowed single molecule 247 
detection 
48
. Until recently, SERS was not widely applied to biomedical research because of 248 
issues linked to complexity of the biological medium, biocompatibility, reproducibility, and 249 
short shelf life. However, using silver and gold colloids as SERS substrates, Bonifacio et al. 250 
recently showed that repeatable spectra could be obtained from protein-free blood serum 251 
and plasma 
49
. 252 
Furthermore, non-linear Raman spectroscopy has been developed to be applied to 253 
biomedical analysis like Stimulated Raman Scattering (SRS) and Coherent Anti-Stokes Raman 254 
Scattering (CARS), for rapid image acquisition (one Raman band at a time) with higher 255 
sensitivities than spontaneous Raman 
50-52
. For non-linear Raman, it is important to know 256 
which marker band(s) are useful, in analogy to the application of Discrete Frequency–IR (DF-257 
IR) as enabled by the use of QCL sources. 258 
Other areas of current interest for Raman spectroscopy are exploring the sampling depth 259 
and location of spectral information. For instance, seminal research conducted by Stone, 260 
Matousek and collaborators, demonstrated the principle of spatially offset Raman 261 
spectroscopy (SORS) for subsurface analysis towards in vivo breast cancer 
53, 54
 and deep 262 
Raman measurements using liquid tissue phantoms to mimic non-invasive cancer screening 263 
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applications in vivo 
55
. Through-tissue sensitivity was increased via SESORS measurements at 264 
several millimetres depth, i.e., combining SORS with nano-tagged SERS particles 
56-59
. 265 
Building on the research described above, the field of biospectroscopy has 266 
continuously progressed and expanded to complex biological systems such as 267 
biofluids 
60
 with a major focus on the development of a potential 268 
diagnostic/prognostic tool with remarkable scope and future clinical promises. 269 
 270 
With the global disease burden set to rise, a more rapid, non-invasive, label-free, non-271 
destructive, automatic and cost effective diagnostic technique like vibrational spectroscopy 272 
would revolutionise the clinical environment. Its utility as a biofluid diagnostic tool is heavily 273 
reliant on the principle that cellular and tissue dysfunction or irregularities affect the 274 
biochemical make-up of biofluids, manifesting as protein, carbohydrate, lipid, and nucleic 275 
acid subtle differences 
16
. 276 
Over the last decade, developments in this field have been ongoing in order to fulfil these 277 
objectives and ultimately leading to better diagnostics and time to results to improve patient 278 
outcomes, offer more efficient public services, and reduce health costs. 279 
 280 
Biomarkers in body fluids 281 
According to the National Institutes of Health definition, a biomarker is “a 282 
characteristic that is objectively measured and evaluated as an indicator of normal 283 
biologic processes, pathogenic processes or pharmacologic responses to a therapeutic 284 
intervention” 
61
. In line with this definition, there is a large range of clinical situations 285 
where the biomarkers are of paramount importance for the patient's management: 286 
screening of patients at risk of the disease or with the disease at an early stage, 287 
differential diagnosis of the disease with other conditions, prognosis of the disease 288 
independently of the treatment, prediction of the response to treatment, monitoring 289 
of disease evolution (Fig. 4). 290 
 291 
Molecular biomarkers may be detectable in tissues and biofluids. Figure 5 illustrates 292 
the case for cancer where tissue biomarkers can be used for cytological or 293 
pathological assessment of the disease or for molecular or spectral imaging 294 
techniques. The tumour is vascularised and markers are shed into the bloodstream. 295 
Another health issue is the early detection of biomarkers for the diagnosis of 296 
infectious diseases coming either from the host or from the pathogen. From the initial 297 
interaction onwards the majority of biomarkers available to measure are derived 298 
from the host since pathogen numbers are very low and the host is able to utilize 299 
components of both the innate and adaptive host response to drive an appropriate 300 
response. In serious infection, when pathogens are able to overcome the early host 301 
response to their presence, their numbers increase at an exponential rate resulting in 302 
significant mortality rates. In such cases, the relative concentration of microbial 303 
biomarkers increase over time whilst biomarkers associated with the ongoing, yet 304 
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ineffective, host response are still readily detectable (Fig. 6). Preliminary evidence has 305 
been produced which indicates that it is possible to identify the presence of an 306 
infectious organism through analysis of host biomarker signatures before patients 307 
become symptomatic 
62
. Thus, the concept of searching for such signatures in host 308 
biofluids pre-symptomatically appears as a promising avenue for exploration in order 309 
to enable early therapeutic intervention. 310 
 311 
Regarding biofluids, blood and its constituents appear the most convenient for 312 
biomarker/biosignature detection given its ease of availability and the possibility to 313 
repeat the test as often as necessary to monitor disease progression or response to 314 
treatment. 315 
 316 
Blood serum houses more than 20 000 different proteins. It perfuses all body organs 317 
meaning it contains a large range of proteomes from surrounding tissues and cells, 318 
making it the most complex biofluid 
63
. The low molecular weight fraction serum 319 
component of blood, known as the “peptidome” is information rich for diagnostic 320 
purposes 
11
. Other biofluids (bile, urine, sputum, pancreatic juice, and ascitic, pleural, 321 
cerebrospinal fluids), in direct contact with the diseased tissue, are of great interest 322 
as media to detect biomarkers/biosignatures that are secreted or shedded locally. 323 
These are expected to be present in higher concentration in these fluids than in the 324 
blood. In addition, their identification may be facilitated by a less complex molecular 325 
composition of local biofluids compared with blood. Although some biofluids such as 326 
urine share with blood samples ease of availability and repeatability, analysis of other 327 
biofluids requires an invasive procedure, which limits their repeated use in the clinical 328 
setting. An example is cerebrospinal fluid which requires a lumbar puncture for 329 
collection.  330 
 331 
Whilst biomedical vibrational spectroscopy has been developed initially mainly for cell 332 
and tissue analysis, it has been also applied more recently to biofluids for biomarker 333 
discovery, generating a number of pilot studies with promising results as presented 334 
below. The challenge is now to translate the results of these exploratory studies to 335 
the routine clinical practice. 336 
 337 
Biofluid Spectroscopy 338 
The search for disease markers in biofluids via photonic approaches is a fast emerging 339 
field and has only been recently explored by vibrational spectroscopic approaches. 340 
Biofluids are easily accessible and minimally invasive for patients making large studies 341 
feasible. Like cells and tissues, biofluids exhibit vibrational spectra that have 342 
characteristic bands reflecting their biomolecular composition. Figure 7 compares the 343 
FTIR spectra of some dried biofluids (serum, plasma, and bile) obtained with a high-344 
throughput module in the transmission mode. IR spectra of serum and plasma 345 
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present very close profiles with subtle differences that are difficult to depict visibly. 346 
This is explained by the fact that serum is essentially plasma with the clotting factors 347 
of blood removed. The assignment of the main bands is provided in Table I. 348 
The bile spectrum differs through a higher lipid and carbohydrate content and by 349 
relative intensity changes of the protein amide I/amide II bands 
64
. 350 
Raman spectroscopy gives complementary information to IR. Besides the main 351 
macromolecules like proteins, lipids, and carbohydrates, other modes originating 352 
from amino acids for example are active. The assignment of the main bands is 353 
indicated in figure 8 showing an example of a typical Raman serum spectrum taken 354 
from a dried drop. 355 
 356 
Serum and plasma 357 
At present, the majority of the biofluid spectroscopy research has focused on serum 358 
and plasma. This is most likely due to the prevalence of these types of samples within 359 
current biobank stocks or the fact that ethics are already established to collect these 360 
samples and all that is required is an addendum stating a separate use of the 361 
material. 362 
Malignant diseases - Currently, in the field of oncology, most investigations are proof-363 
of-principle studies showing the potentials of FTIR/Raman spectroscopy to identify 364 
different types of cancer from serum samples with high degrees of accuracy. HT-FTIR 365 
spectroscopy in transmission mode was used to discriminate urinary bladder cancer 366 
patients from patients with urinary tract infection with linear discriminant analysis 367 
(LDA) or random forest (RF) classifiers 
65
. Using blood serum, Backhaus et al. 368 
distinguished between breast cancer and controls with a very high sensitivity and specificity 369 
66
. Chemometrics combining support vector machine (SVM) and leave-one-out cross 370 
validation was employed by Zhang et al. to separate cirrhotic patients with or without 371 
hepatocellular carcinoma 
67
. Equally important is the possibility to identify liver 372 
fibrosis stages prior to the development of hepatocellular carcinoma, which are 373 
crucial for the clinical management. A study by Scaglia et al. revealed that patients 374 
with extensive fibrosis (F3/F4 stages) could be distinguished from those with no 375 
fibrosis (F0 stage) on the basis of their FTIR serum spectra using a combination of 376 
discriminant wavenumbers 
68
. Studies using ATR-FTIR spectroscopy, coupled with 377 
classification machine discriminated ovarian 
69
 and endometrial cancers 
70
. It also 378 
allowed differentiating glioblastoma multiforme (GBM) from healthy control and low 379 
grade gliomas and GBM versus healthy control 
71, 72
. 380 
Applications of Raman spectroscopy to the study of various biofluids from cancer 381 
patients are in continuous progress. Sahu et al. analysed serum samples and could 382 
differentiate oral cancer patients from controls 
73
. More recently, they reported that 383 
Raman serum spectroscopy was capable to predict the probability of recurrence in 384 
this cancer 
74
. Other studies have shown the potential of Raman spectroscopy for 385 
differentiating normal subjects from patients with breast 
75
, colorectal 
76
, or cervical 
77
 386 
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cancers. A proof-of-concept study using micro-Raman spectroscopy applied to the 387 
sera of 71 cirrhotic patients showed that it could be an alternative method for 388 
discriminating cirrhotic patients with and without hepatocellular carcinoma 
78
. On the 389 
other hand, SERS of serum or plasma has also been shown as a promising tool for the 390 
diagnosis of various types of cancer such as nasopharyngeal 
79-81
, digestive 
80, 82-84
, and 391 
prostate cancers 
85
. 392 
 393 
 394 
Non-malignant diseases - Serum and plasma have been also employed to diagnose 395 
other diseases using biospectroscopy. For example, Raman serum data allowed to 396 
differentiate Alzheimer’s disease from other dementia 
86
 and Carmona et al. used 397 
plasma Raman spectral data to grade mild, moderate, and severe Alzheimer cases 
87
. 398 
Via FTIR spectroscopy of plasma, Peuchant et al. have shown that patients with 399 
Alzheimer’s disease could be well delineated from normal ageing subjects used as 400 
controls 
88
. 401 
 402 
Recent plasma data published by Lacombe et al. clearly showed that HT-FTIR 403 
spectroscopy could be an interesting alternative technique in neonatal screening of 404 
rare diseases such as classic galactosemia. Promising results indicated that 405 
healthy/diabetic, healthy/galactosemic, and diabetic/galactosemic patients could be 406 
discriminated with good sensitivity and specificity 
89
. 407 
 Few large studies have been reported. An example is the study led by Petrich’s group 408 
showing the potential of mid-infrared spectroscopy in the triage of patients with 409 
acute chest pain 
90
. This study included 1429 serum samples from 389 patients 410 
reporting to two US hospitals (Massachusetts General and Latter Day Saints, Utah) 411 
consisted of 104 suffering from acute myocardial infarction (AMI), 136 from unstable 412 
angina pectoris, and 149 from chest pain of other sources. FTIR measurements were 413 
performed in the transflection mode. Using a threshold value generated from a 414 
robust linear discriminant analysis, they achieved high sensitivity and specificity 415 
enabling triage of patients with AMI, those most at need within the Accident and 416 
Emergency setting, compared to the other sources of chest pain. They hypothesise on 417 
the involvement of carbohydrates as discriminant features, possibly a glycation 418 
reaction. Interestingly, their results were comparable to the performance of routine 419 
cardiac laboratory markers within the same study population. They conclude on the 420 
potential of FTIR to aid the diagnostic procedure as early as within the first 6 hours 421 
after the onset of chest pain. 422 
Blood plasma from patients has been investigated with Raman spectroscopy as dried 423 
drops to identify a reliable biomarker that can differentiate sepsis patients from those 424 
with non-infectious systemic inflammatory response syndrome. Neugebauer et al. 425 
reported on the high sensitivity and specificity that can be achieved 
91
. The possibility 426 
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of separating the two groups of patients is crucial because a stratification of at risk 427 
patients can be established for a rapid delivery of appropriate treatment.  428 
Finally, following the results obtained in a model of infected cultured cells, SERS appears as a 429 
promising approach for malaria parasite detection from whole blood 
92
. 430 
 431 
Other biofluids  432 
Other biofluids non-invasively accessible (urine, saliva, sputum, tears) and invasively 433 
accessible (bile, synovial fluid, cerebrospinal fluid, amniotic fluid) have been 434 
investigated by vibrational spectroscopy for diagnostic purposes. 435 
Somorjai et al. were able to distinguish urine samples from normal renal transplants 436 
and rejected allografts, applying IR spectroscopy and a three-stage classification 437 
strategy 
93
. A Raman spectroscopic analysis combined with PCA and quadratic 438 
discriminant analysis (QDA) performed on urine, has allowed identification of spectral 439 
biomarkers predictive of complications and kidney failure in the urine of diabetic and 440 
hypertensive patients 
94
. Finally, in the field of oncology, Del Mistro et al. reported 441 
that SERS using Au nanoparticle substrates had the potential to detect in urine 442 
spectral biomarkers of prostate cancer 
95
. 443 
Another approach by FTIR spectroscopy associated with LDA on saliva, has reported the 444 
correct classification of diabetic patients from healthy control 
96
. SERS of saliva showed the 445 
ability to predict lung cancer by monitoring the decrease of proteins and nucleic acids with 446 
80%, 78%, and 83% accuracy, sensitivity, and specificity respectively 
97
. A preliminary study 447 
using SERS on saliva suggested the possibility of a quick detection of AIDS but these results 448 
obtained on a small number of patients deserve to be confirmed on a larger population 
98
. 449 
An exploratory study has shown that FTIR spectroscopy applied to sputum could be a 450 
useful approach for the diagnostic of the chronic obstructive pulmonary disease 
99
. 451 
Investigating the potential of human tears for the diagnosis of ocular diseases, Travo 452 
et al. have shown the discrimination of patients with keratoconus (degenerative 453 
disorder affecting the cornea) from healthy control and also between patients at an 454 
early or advanced stage of disease by HT-FTIR and PCA 
100
. Additionally, Choi et al. 455 
report that SERS can be used for diagnosis of adenoviral conjunctivitis from tears 
101
. 456 
Using HT-FTIR spectroscopy in association with support vector machine (SVM) 457 
classification and leave-one-out cross validation (LOOCV), Untereiner et al. have 458 
shown that bile samples of patients with malignant biliary strictures were 459 
differentiated from those with benign biliary diseases 
64
. 460 
Eysel et al. using FTIR spectroscopy and LDA with LOOCV on synovial fluid, were able 461 
to differentiate samples from joints affected by rheumatoid arthritis, osteoarthritis, 462 
spondyloarthropathies, and meniscal injuries 
102
. Also from synovial fluid samples, a 463 
Raman spectroscopic study associated to a k-means analysis has shown discrimination 464 
between patients with osteoarthritis of low or high severity 
103
. 465 
Liu et al. have investigated the amniotic fluid potential for fetal lung development 466 
assessments by IR spectroscopy. The lecithin/sphingomyelin (lung surfactants) and lung 467 
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surfactant/albumin ratio measurements by IR spectroscopy were quantitatively and 468 
qualitatively correlated to those obtained by thin-layer chromatography and fluorescence 469 
depolarization, two clinical methods used to determine fetal lung surfactant maturity in 470 
amniotic fluid 
104
. Prenatal disorders from amniotic fluids have also been investigated by 471 
ATR-FTIR spectroscopy revealing spectral profile changes between amniotic fluids from 472 
pregnancies with fetal malformations, preterm delivery and healthy term pregnancies 
105
. 473 
Griebe et al. were able by FTIR spectroscopy to distinguish patients with Alzheimer’s disease 474 
from healthy controls using cerebrospinal fluid 
106
. 475 
 476 
 Translation 477 
With a few exceptions, all the mentioned proof-of-concept studies have been carried 478 
out on rather small populations and have shown promises for clinical utility and 479 
highlight the potential of vibrational spectroscopy for spectral diagnostics. To our 480 
knowledge, two major programmes for large scale clinical trials in remote settings are 481 
ongoing using hand-held FTIR modalities. The first campaign led by Wood et al. 482 
concerns the screening of population in Thailand for malarial diagnosis 483 
(http://monash.edu/news/show/infrared-light-puts-malaria-to-the-test). 484 
A similar approach is being taken in the UK with the establishment of Glyconics Ltd. 485 
Glyconics is using sputum to diagnose Chronic Obstructive Pulmonary Disorder and 486 
are moving towards clinical validation of handheld ATR-FTIR on a subset of the UK 487 
population (http://www.glyconics.com/technology.asp). 488 
 489 
These steps towards actual clinical environment testing is pushing the field to the 490 
forefront of the application and will illuminate the utility of these techniques as well 491 
as barriers to clinical implementation that need to be overcome. 492 
 493 
Multivariate Analysis
 
494 
It is becoming more and more evident that vibrational spectroscopy represents an 495 
interesting approach to explore the diagnostic potentials of circulating 496 
biomarkers/biosignatures in various body fluids 
60
. Along with the technological 497 
development, the front-end sample preparation challenges and approaches, and the 498 
data acquisition procedures, the pre-processing and post-processing of spectral data 499 
are equally important for the deployment of various biofluid classes into diagnostics 500 
development. Vibrational spectroscopic data are inherently multivariate by nature 501 
and their pre- and post-processing require multivariate data analysis approaches. 502 
 503 
Different instruments from different manufacturers have different responses and 504 
spectral distortions and backgrounds have to be taken into account via pre-processing 505 
algorithms in order to compare data from different studies for example. The pre-506 
processing should therefore be able to give accurate, robust and reliable data. These 507 
considerations should also include how the sample is prepared and conditioned, the 508 
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optical substrate used, and the acquisition mode used in order to post-process 509 
reliable data. The way the sample is dried or acquired (e.g. transmission or reflection) 510 
will also pre-empt the pre-processing procedures. For example, rapid drying of serum 511 
can produce a granulating effect which then causes more scattering/dispersion 512 
artefacts and a specific correction has to be implemented. It is clear that the pre-513 
processing is not the same for infrared and Raman spectra of biofluids because the 514 
physical phenomena involved are respectively absorption and scattering. In FT-IR 515 
spectroscopy the use of an interferometer ensures an excellent intensity and 516 
wavenumber calibration. In addition, a background signal is regularly recorded and 517 
automatically subtracted to obtain the sample spectrum. For Raman, a day-to-day 518 
calibration procedure needs to be implemented to correct for instrument response, 519 
and to calibrate the wavenumber and intensity axes. Other experimental 520 
considerations include the need to subtract substrate contributions and other 521 
physical phenomena such as fluorescence and heating. Biofluid vibrational spectra are 522 
therefore corrected, derived (or not), then normalized. As a general rule, it is also 523 
important to include prior to the pre-processing steps, a quality test to remove 524 
spectra with a poor signal/noise ratio (threshold to be defined depending on the 525 
sample nature) and a validated outlier removal routine before post-processing. 526 
 527 
The post-processing step includes data mining and the construction of classifiers. Very 528 
often, the spectral differences between normal and pathological states are very 529 
subtle and the next step is to perform data mining, i.e., a process used to extract the 530 
salient information from the spectral data. By using specific algorithms, patterns can 531 
be found in large batches of data. Thus, such feature selection procedures can help to 532 
identify discriminant spectral features to discriminate between patient groups 
67
. 533 
However, it is important to note that data mining depends on effective data 534 
collection, the size of the datasets, and as well as their pre-processing. 535 
 536 
To build classification models, several multivariate approaches have been used and as 537 
of today there is no general consensus on which method is the best. In other research 538 
fields, numerous linear and non-linear supervised algorithms have been evaluated 539 
and a combination of methods like SVM and PLS-DA has been shown to enhance the 540 
sensitivity and specificity of the classifiers 
107
. Generally, building the classifier should 541 
include a calibration phase (training phase), an internal validation phase, and an 542 
external validation phase (blind testing phase). One of the important issues 543 
encountered is the size of the datasets used as a small dataset that does not 544 
accurately describe the patient population can lead to under- or over-fitting and 545 
impact the classifier outcome. For a classifier to be robust, it is important to have a 546 
large number of class-representative patient samples. In addition, the external 547 
validation requires a dataset that has not been used in the two previous steps of 548 
calibration and internal validation (based upon patient spectra and not replicate 549 
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spectra from the same patient i.e. a spectrum from the same patient should not be in 550 
the calibration/internal validation and external validation phases). The leave-n-out 551 
cross validation method is often used for these models. It is important to note that all 552 
spectra from a given patient must be removed in this process in order to enable a 553 
valid outcome. Considering all individual spectra, mean spectra or median spectra as 554 
input datasets of the classifier should also be taken into consideration although it has 555 
been found that when spectra are highly reproducible and after applying a quality 556 
control test plus an appropriate outlier removal, the results are comparable 
64
. 557 
 558 
The workflow in figure 9 illustrates the different steps, for both IR and Raman 559 
spectroscopies, starting from sample preparation to data pre- and post-processing 560 
and the building of classifiers for diagnostics. The issues dealing with pre-processing 561 
and post-processing procedures generally used are described in a more detailed 562 
manner in a dedicated review elsewhere in this special issue. 563 
 564 
Requirements for Clinical Implementation  565 
Over the last 20 years, the number of studies dedicated to identification of new 566 
biomarkers has increased exponentially, mainly because of the tremendous 567 
development of high-throughput molecular technologies and associated 568 
bioinformatics. However, among the huge amount of candidate biomarkers, only a 569 
limited number have been validated for use in medical practice 
108
. The origin of this 570 
discrepancy has been extensively analyzed in the field of proteomics and genomics. 571 
Methodological flaws have been identified in the process of their identification 572 
and/or clinical validation and recommendations have been set forth to overcome 573 
these inadequacies 
109-111
. Studies based on vibrational spectroscopy are subject to 574 
the same problems. As for other high throughput technologies, the huge amount of 575 
data generated by spectroscopic analysis exposes this analysis to a significant risk of 576 
false positive findings. This risk should be minimized by rigorously controlling sample 577 
and patient related factors in the exploratory phase and by standardizing the 578 
conditions of spectral acquisition, processing and analysis (preanalytic/analytic 579 
validity). Subsequently, the findings from pilot studies need to be confirmed in 580 
independent large cohort of samples (clinical validity) and finally the benefit of using 581 
the biomarker/biosignature in the clinical decision-making setting should be clearly 582 
demonstrated as well as its favourable medico-economic profile. Only after this 583 
process, a newly discovered biomarker can pretend to reach the routine clinical use 584 
109-113
. 585 
 586 
 Preanalytic/analytic validity 587 
In the preanalytic step, attention should be paid to validate sample-related factors 588 
and patient-related factors. Standardization of specimen collection and storage is 589 
crucial to reach experimental reproducibility not only in an individual laboratory but 590 
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also between different laboratories. In addition, investigators should be aware of the 591 
risks of contamination during sample handling. In a recent SERS study 
49
, EDTA, citrate 592 
and Li-Heparin used as anticoagulants for plasma collection have been shown to 593 
exhibit confounding peaks. When using filtered plasma (with a 3kDa cut-off), contrary 594 
to EDTA and citrate, Li-Heparin was filtered out and no longer interfered with the 595 
spectral information. FTIR studies have shown that EDTA and citrate spectral 596 
contributions can be circumvented using dialysed plasma. In contrast, no interference 597 
in FTIR spectra was observed when directly analysing plasma from Li-Heparin tubes 598 
114
. Due to these limitations, serum is often preferred to plasma in spectroscopic 599 
analysis. Factors related to patients are of paramount importance to limit the risk of 600 
false positives.  Inappropriate selection of case patients and control subjects is a 601 
common pitfall in spectroscopic studies as widely reported in other high throughput 602 
technologies 
108, 115
. When comparison groups are not matched for example for age, 603 
sex and physical conditions such as hormonal status or pathologies other than the 604 
disease of interest, results may be biased and differences identified between groups 605 
may be linked to these confounding factors rather than to the disease of interest 
109
. 606 
Analytic validity includes the technical aspects of the biomarker assessment. In the 607 
field of vibrational spectroscopy, the interaction of light with biological molecules is 608 
subject to a certain number of drawbacks which should be overcome to meet the 609 
criteria of accuracy, reproducibility and robustness.  610 
 611 
The most common protocol for spectral analysis of biofluids is the drying of drop 612 
deposits. A shortcoming of this method is the heterogeneous drop deposition 613 
characterized by the well-known coffee-ring effect, due to the migration of 614 
macromolecules towards the periphery of the drop 
116-118
. In order to clarify the 615 
dynamics of such deposition, Esmonde-White et al. used both imaging and Raman 616 
spectroscopy to demonstrate that substrate and fluid concentration have a profound 617 
effect on dried drop morphology. They showed that the substrate did not affect the 618 
chemical composition within the outer ring of the drop whereas the macromolecular 619 
concentration has an impact on the spatial distribution of proteins 
119
. Using HT-FTIR, 620 
Lovergne et al. have recently confirmed the impact of serum dilution on the 621 
deposition pattern as illustrated in figure 10 
120
. Without dilution, serum spectra were 622 
saturated, due to the acquisition in the transmission sampling mode. The 3-fold 623 
dilution was shown to be the most suitable for spectral analysis with a good 624 
reproducibility and absorbance intensity. The signal/noise ratio was degraded with 625 
higher fold dilutions which precludes the analysis of molecules present at a low 626 
concentration in the serum. The heterogeneous deposition of macromolecules in the 627 
outer ring should be taken into account when using mode point spectroscopic 628 
assessment. It has been reported that this issue can be overcome by averaging 629 
spectra taken at different points of the outer ring 
121
. Another possibility to avoid the 630 
coffee-ring effect is to perform an analysis on a film composed of an array of reduced-631 
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size dry drops each formed from 200 pL of serum 
122
. The strict control of 632 
experimental parameters of drop deposition appears as a major prerequisite to 633 
obtain reproducible results 
119
. This may be obtained at best by an automated 634 
sampling approach as described by Ollesch et al. Using this approach, these authors 635 
have reported a higher reproducibility of spectral data compared to a non-automatic 636 
sampling 
122
. 637 
 638 
ATR-FTIR spectroscopy has been shown to be an interesting approach for the analysis 639 
of biofluids as samples can be directly applied onto the ATR crystal without any 640 
dilution. However, currently there is no automated device available so that spectral 641 
acquisition is time consuming, about 9 times longer than with automated HT-FTIR 642 
spectroscopy 
120
. The lack of automation is a limiting factor for the transposition of 643 
ATR-FTIR spectroscopy into a high-throughput clinical application 
123
.
 
This may also be 644 
possible when using a high throughput source such as a QCL during a DF-IR approach. 645 
However, for limited patient cases, in a hand-held mode it offers advantages of ease 646 
of use and ease of sample preparation with no modification/adulteration of the 647 
sample. Identically, Raman spectroscopy is also of great interest for biofluid 648 
spectroscopy particularly due to developments in hand held technology and 649 
immersion Raman which could enable hand held analysis of “wet” serum, negating 650 
the need for a drying step. 651 
 652 
The technical standardization of spectral acquisition makes sense if reproducible 653 
results can be obtained in different laboratories. This external validation is essential 654 
on the way towards clinical validity. The inter-instrument transferability is also a 655 
challenge that needs to be faced. Finally, the need for automated instruments 656 
underline the necessity of a close collaboration between research scientists, clinical 657 
practitioners and industrial partners in order to optimize currently available products 658 
according to a specific biomedical purpose 
1
. 659 
Beside the need of standardized spectral acquisition, there is also a need to validate 660 
the design of pilot studies including the chemometric analysis. Proof-of-concept 661 
studies raise the question of appropriate selection of case patients and controls as 662 
discussed below and also the question of sample size. In contrast with classical 663 
statistics, there is no simple method to calculate sample size in biospectroscopic 664 
studies. However, Beleites et al. have proposed in a recent report to use learning 665 
curves to determine the appropriate sample size needed to build good classifiers with 666 
specified performances 
124
. When the number of patients is too limited to divide the 667 
population in one training set and one independent validation set, cross validation 668 
methods should be used to avoid the high risk of overfitting 
125
. 669 
 670 
 Clinical validity 671 
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The next step after the phase of pre-analytic/analytic validation is to confirm the 672 
diagnostic performance of the biomarker on an independent population of a large 673 
number of patients. This means large multicenter randomized control trials where the 674 
sensitivity and the specificity of the putative biomarker may be evaluated against the 675 
gold standard diagnostic/screening procedure. These studies, particularly the criteria 676 
to include case patients and controls, should be carefully designed to demonstrate 677 
whether the biomarker is applicable to its specific purpose which may be screening, 678 
differential diagnosis, prognosis, treatment response prediction or monitoring of a 679 
disease (Fig. 4). 680 
 681 
A common mistake is to validate a marker in the diagnostic setting of a disease and 682 
then to extrapolate its performance to the screening context. Candidate biomarkers 683 
are tested in pilot studies performed in small numbers of patients with patent disease 684 
already diagnosed using golden standard methods. It is crucial to validate the value of 685 
these markers in the screening context i.e. for early diagnosis in large populations of 686 
patients at risk of the disease. The biomarker sensitivity and specificity in the 687 
screening target population are usually much lower than in patients with patent 688 
disease. In the context of population screening, high specificity is of paramount 689 
importance to avoid false positive results, which means patients will be subject to 690 
additional diagnostic procedures, potentially invasive and costly for the society. This 691 
underlines the necessity of selecting case patients and control subjects according to 692 
the clinical setting where the biomarker is intended to be used 
109
. 693 
 694 
A methodology to avoid patient selection bias in screening studies has been proposed 695 
by Pepe et al. 
109, 111, 126
. In the so-called PRoBE study design, samples are collected 696 
prospectively in a cohort of patients before the knowledge of the final diagnosis. 697 
Once the outcome data becomes available and the diagnosis established, the sample 698 
cohort can be used retrospectively by randomly selecting cases and controls. This 699 
methodology is promoted by the research consortium "Early Detection Research 700 
Network" from the National Cancer Institute to establish specimen reference sets. It 701 
has proved efficient for rapid evaluation of potential biomarkers 
110
. 702 
 703 
 Clinical utility 704 
A crucial point in the process of biomarker validation before its adoption in routine 705 
clinical practice is to demonstrate its clinical decision-making usefulness at an 706 
acceptable cost for the society 
109
. This means that the positive and negative 707 
predictive values of the biomarker should be evaluated in the “real life” patient 708 
population since these indicators are dependent on the prevalence of the disease of 709 
interest. The difference between clinical validity and clinical utility is illustrated by the 710 
debate about the usefulness of Prostatic Specific Antigen (PSA)-based screening 711 
program. It is well established that PSA-based screening programs significantly 712 
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increase the detection of prostate cancer at an early stage 
127
. However, there is also 713 
evidence that PSA-based screening carries a high risk of over-diagnosis leading to 714 
overtreatment in a significant number of men with early cancer that will never 715 
become symptomatic during their life time 
128
. Whether the benefits of early 716 
detection of asymptomatic prostate cancer outweigh the harms related to over-717 
diagnosis and overtreatment is highly controversial. There is no consensus regarding 718 
the clinical relevance of a PSA-based screening program 
129
. This emphasizes that, in 719 
addition to its diagnostic performance, the biomarker clinical utility has to be 720 
demonstrated before its clinical implementation. The clinical utility refers to the 721 
balance of benefits to harms and the medicoeconomic evaluation. For this purpose, a 722 
validation study should be performed in a large number of unselected patients with 723 
clinical endpoints clearly defined to demonstrate the benefit of using a biomarker 724 
including quality of life for the patient and socioeconomic aspects for the society 
109
. 725 
 726 
Conclusion 727 
The difficulty in translating biomedical spectroscopy to the clinic is fundamentally 728 
based in the fact that after over more than two decades of research, not enough has 729 
been done to fully understand the accuracy of these tests with appropriate 730 
considerations applied to control groups and limitations of the clinical environment. 731 
In addition there is a need to perform large-scale studies to evaluate the 732 
spectroscopic tests’ efficacy within the clinic. These approaches would also enable a 733 
“diplomatic mission” to enable this technology to be acceptable to the medical 734 
community through a “hearts and minds” approach. The particular requirements and 735 
picture of a clinical spectrometer or suit of spectrometers including the spectroscopic 736 
approach should be implemented for different clinical settings, its instrumental 737 
requirements (e.g. detector sensitivity and source throughput), and how accurately it 738 
can diagnose disease or perform treatment monitoring. 739 
 740 
This review has highlighted the increased diagnostic sensitivity observed from the use 741 
of biomedical vibrational spectroscopy to analyse biofluids. However, care should be 742 
taken for biofluid spectroscopy not to suffer from the identified pitfalls. As the field of 743 
biofluid spectroscopy is further researched, a lot of commitment from different 744 
stakeholders (researchers, clinicians, and instrument manufacturers) will be necessary 745 
to demonstrate its real potential as a rapid, novel, and robust technology to pinpoint 746 
“spectral biomarkers / signatures” that can be useful for diagnostic purposes and to 747 
predict clinical outcomes, with the promise that the test can be done periodically at 748 
low cost for monitoring care. 749 
 750 
The initiatives via current networks like the EPSRC CLIRSPEC (http://clirspec.org/), the 751 
Raman4Clinics European COST action (http://www.raman4clinics.eu/raman4clinics-a-752 
european-cost-action/) and the 1
st
 International Society for Clinical Spectroscopy 753 
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(CLIRSPEC) are currently gearing research, facilities and communities in the clinical 754 
spectroscopy arena to achieve these objectives. 755 
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Table I: Assignment of the major absorption bands of a plasma FT-IR spectrum 
89
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 777 
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 779 
 780 
Fig. 1 Energy diagram showing transitions involved during infrared absorption, Rayleigh, 781 
Raman Stokes and anti-Stokes scattering. This Jablonski diagram shows that the same 782 
vibrational states of a given molecule can be probed via two different routes; one directly 783 
measures the absolute frequency (IR absorption) and the other measures the relative 784 
frequency or Raman shift (Stokes and anti-Stokes). hvo= incident laser energy, hvvib = 785 
vibrational energy, Δυ = Raman shift, υvib = vibrational frequencies. 786 
 787 
Fig. 2 Number of publications returned in PubMed when inputting the term "cancer 788 
biomarker" (a) and “infection biomarkers” (b). 789 
 790 
Fig.3 FTIR biological spectrum showing frequent biomolecular band assignments from 3,000-791 
800 cm
-1
, where ν = stretching vibrations, δ = bending vibrations, s = symmetric vibrations 792 
and as = asymmetric vibrations. Illustration taken from transmission spectra on human 793 
breast ductal carcinoma, prepared on 1mm thick BaF2 slides 
4
.The 3000-2800 cm
-1
 region 794 
originates mostly from lipids (CH, CH2 and CH3 stretching modes), but protein absorption of 795 
the same modes also contribute to these absorption bands. 796 
 797 
Fig. 4 Schematic of biomarker use in clinical practice. 798 
 799 
Fig. 5: Example of potential tumour-site related biomarkers. 800 
 801 
Fig. 6 The relative contribution of host and microbial derived biomarkers to enable 802 
diagnosis of infection. 803 
 804 
Fig. 7 Comparison between HT-FTIR spectra of different biofluids: serum (red curve), 805 
plasma (blue curve), and bile (green curve). Spectra are background corrected and 806 
normalised. Note: Serum and bile were collected in dry tubes while for plasma 807 
samples lithium heparin tubes were used. 808 
Bands (cm
-1
) Major assignments for plasma contents 
3300 ν(N-H) of proteins (amide A band) 
3055-3090 ν(=CH) of lipids 
2950-2960 νas(CH3) of lipids 
2920-2930 νas(CH2) of lipids 
2865-2880 νs(CH3) of lipids 
2840-2860 νs(CH2) of lipids 
1730-1760 ν(C=O) of fatty acids 
1660 ν(C=O) of proteins (amide I band) 
1550 δ(N-H) of proteins (amide II band) 
1400 ν(COO
-
) of animo acids 
1240 νas(P=O) of nucleic acids 
1170-1120 ν(C-O) and ν(C-O-C) of carbohydrates 
ν: stretching vibrations, δ: bending vibrations , s: symmetric, 
as: asymmetric. Taken from Lacombe et al., Analyst, 2015, 140, 2280. 
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Fig. 8 Typical Raman spectrum of dried serum drop with spectral assignments. Spectrum was 809 
measured on a calcium fluoride window with a 785 nm laser excitation with an acquisition 810 
time of 2x30 seconds. 811 
 812 
Fig. 9 Workflow of biofluid spectroscopy from substrate choice through sample preparation 813 
to spectral measurements and data analysis with diagnostic classifiers. 814 
 815 
Fig. 10 Analysis of dried serum drops and coffee ring effect with different dilutions: white 816 
light images (left) and chemical images constructed on amide I protein band (right). 817 
 818 
 819 
  820 
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Energy diagram showing transitions involved during infrared absorption, Rayleigh, Raman Stokes and anti-
Stokes scattering. This Jablonski diagram shows that the same vibrational states of a given molecule can be 
probed via two different routes; one directly measures the absolute frequency (IR absorption) and the other 
measures the relative frequency or Raman shift (Stokes and anti-Stokes). hvo= incident laser energy, hvvib 
= vibrational energy, ∆υ = Raman shift, υvib = vibrational frequencies.  
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FTIR biological spectrum showing frequent biomolecular band assignments from 3,000-800 cm-1, where ν = 
stretching vibrations, δ = bending vibrations, s = symmetric vibrations and as = asymmetric vibrations. 
Illustration taken from transmission spectra on human breast ductal carcinoma, prepared on 1mm thick 
BaF2 slides.[4]  
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Schematic of biomarker use in clinical practice.  
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Example of potential tumour-site related biomarkers.  
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The relative contribution of host and microbial derived biomarkers to enable diagnosis of infection.  
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Comparison between HT-FTIR spectra of different biofluids: serum (red curve), plasma (blue curve), and bile 
(green curve). Spectra are background corrected and normalised. Note: Serum and bile were collected in 
dry tubes while for plasma samples lithium heparin tubes were used.  
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!
Typical Raman spectrum of dried serum drop with spectral assignments. Spectrum was measured on a 
calcium fluoride window with a 785 nm laser excitation with an acquisition time of 2x30 seconds.  
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Workflow of biofluid spectroscopy from substrate choice through sample preparation to spectral 
measurements and data analysis with diagnostic classifiers.  
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Analysis of dried serum drops and coffee ring effect with different dilutions: white light images (left) and 
chemical images constructed on amide I protein band (right).  
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